DESLORA-DENK 5 Tablets/Film-coated

DESLORA-DENK 5 features an exceptional active ingredient renowned for its potent effects, comprising Desloratadine. This powerful formulation provides a superior solution for addressing diverse health concerns. With 5mg/Tablet concentration and an easily manageable Tablets/Film-coated, it remains a preferred option for countless individuals seeking effective treatment.

What is DESLORA-DENK 5 ?

Overview of FENOFIBRATE: FENOFIBRATE is a medication primarily used to manage abnormal lipid levels in the blood, particularly high triglycerides and low levels of high-density lipoprotein (HDL) cholesterol. It is classified as a fibrate and works by activating the peroxisome proliferator-activated receptor alpha (PPAR-alpha), which regulates the metabolism of lipids. This action leads to decreased triglyceride synthesis in the liver, increased fatty acid oxidation, and enhanced clearance of triglyceride-rich lipoproteins from the bloodstream.

Clinical Indications: FENOFIBRATE is commonly prescribed for patients with hyperlipidemia, especially those who have not achieved adequate lipid control through lifestyle modifications alone. It is often used in conjunction with a cholesterol-lowering diet and may be combined with statins in patients requiring more intensive lipid management.

How to use DESLORA-DENK 5 ?

How to Take FENOFIBRATE: For the best results, follow these administration guidelines:

• Dosage: The typical starting dose of FENOFIBRATE is 48 mg or 145 mg taken once daily, depending on the patients specific condition and response to treatment.
• Administration: Take the medication with food to enhance absorption and minimize potential gastrointestinal side effects.
• Consistency: It is essential to take FENOFIBRATE at the same time each day to maintain steady levels of the medication in your system.
• Missed Dose: If you forget a dose, take it as soon as you remember unless it’s almost time for your next dose. Do not double the dose to catch up.
• Consultation: Always consult your healthcare provider for advice regarding dosing, especially if you have questions or concerns about your treatment regimen.

<

Mode of Action

Mechanism of Action of FENOFIBRATE: The primary mechanism of FENOFIBRATE involves several key actions in lipid metabolism:

• Activation of PPAR-alpha: FENOFIBRATE selectively activates PPAR-alpha, leading to increased fatty acid oxidation and reduced triglyceride levels.
• Reduced VLDL Production: By inhibiting the synthesis of very-low-density lipoprotein (VLDL), FENOFIBRATE decreases triglyceride levels in the blood.
• Enhanced Lipoprotein Clearance: The medication increases the uptake and clearance of triglyceride-rich lipoproteins from circulation, promoting a healthier lipid profile.
• Increased HDL Levels: FENOFIBRATE is known to elevate levels of HDL cholesterol, which is protective against cardiovascular diseases.
• Improved Insulin Sensitivity: Some studies suggest that FENOFIBRATE may improve insulin sensitivity, contributing to better metabolic control in diabetic patients.

DESLORA-DENK 5 Interactions

Drug Interactions with FENOFIBRATE: Understanding potential interactions is crucial for safe and effective use:

• Statins: Combining FENOFIBRATE with statins can increase the risk of myopathy or rhabdomyolysis; careful monitoring is essential.
• Anticoagulants: FENOFIBRATE may potentiate the effects of anticoagulants like warfarin, requiring regular monitoring of coagulation parameters.
• Other Lipid-Lowering Agents: The additive effects of combining FENOFIBRATE with other antihyperlipidemic medications can lead to enhanced lipid control but may also necessitate careful monitoring for side effects.
• Renal Function: Patients with impaired renal function may require dose adjustments; caution is advised in this population.
• CYP450 Interactions: Certain medications affecting CYP450 enzymes can alter the metabolism of FENOFIBRATE, impacting its safety and efficacy.

Dosage of DESLORA-DENK 5

Dosage Recommendations for FENOFIBRATE: Following appropriate dosage is vital for treatment success:

• Standard Dose: The usual starting dose is either 48 mg or 145 mg taken once daily, based on the patient’s lipid levels and clinical response.
• Adjustment for Renal Impairment: For patients with renal impairment, a lower dose may be required to avoid adverse effects.
• Regular Monitoring: Patients should have lipid panels checked regularly to assess the effectiveness of therapy and make necessary dosage adjustments.
• Duration of Treatment: FENOFIBRATE is typically used as a long-term therapy; discontinuation should only occur upon the advice of a healthcare provider.
• Patient Compliance: Stressing the importance of adhering to the prescribed dosing schedule is crucial for optimal outcomes.

Possible side effects of DESLORA-DENK 5

Possible Side Effects of FENOFIBRATE: Being aware of side effects is important for all patients:

• Common Side Effects: Commonly reported side effects include gastrointestinal issues such as nausea, abdominal pain, and diarrhea.
• Skin Reactions: Some patients may experience rashes or itching, which could signify an allergic reaction.
• Liver Function Abnormalities: FENOFIBRATE can cause elevations in liver enzymes, necessitating regular liver function tests.
• Myopathy: Patients should report any unexplained muscle pain or weakness, particularly when taking statins concurrently.
• Increased Creatinine Levels: Monitoring for elevated creatinine levels is advised, as FENOFIBRATE may affect renal function.

DESLORA-DENK 5 Contraindications

Contraindications for FENOFIBRATE: Certain conditions may prevent the use of this medication:

• Hypersensitivity: Patients with a known hypersensitivity to FENOFIBRATE should avoid its use.
• Severe Renal Impairment: FENOFIBRATE is contraindicated in individuals with severe renal impairment due to the risk of accumulation.
• Active Liver Disease: Those with active liver disease should not use FENOFIBRATE, as it may worsen their condition.
• Pregnancy and Lactation: FENOFIBRATE is generally not recommended during pregnancy or breastfeeding; alternatives should be considered.
• Gallbladder Disease: Patients with a history of gallbladder disease should be cautious, as FENOFIBRATE can increase the risk of gallstones.

Storage of DESLORA-DENK 5

Storage Conditions for FENOFIBRATE: Proper storage is essential to ensure the medication’s effectiveness:

• Room Temperature: Store at a controlled room temperature, between 20°C and 25°C (68°F to 77°F), away from direct light and moisture.
• Original Packaging: Keep FENOFIBRATE in its original packaging to protect it from light and humidity.
• Child Safety: Ensure that the medication is stored out of reach of children to prevent accidental ingestion.
• Expiration Awareness: Regularly check the expiration date and properly dispose of expired medications according to local regulations.
• Avoid Humidity: Do not store FENOFIBRATE in damp areas, as moisture can degrade the medication.